Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$15.31
-0.2%
$13.90
$6.38
$16.66
$1.49B1.571.44 million shs1.46 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.68
-2.1%
$14.68
$12.79
$55.70
$1.59B1.022.50 million shs1.83 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$32.31
-1.1%
$25.63
$10.81
$33.63
$473.38M0.31121,077 shs70,513 shs
Vericel Corporation stock logo
VCEL
Vericel
$31.79
+5.2%
$35.10
$29.24
$63.00
$1.53B1.33926,935 shs1.21 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
0.00%-5.31%+3.93%+73.33%+20.31%
Biohaven Ltd. stock logo
BHVN
Biohaven
0.00%+4.53%-2.37%+6.24%-70.61%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%+18.41%+15.89%+129.01%+110.57%
Vericel Corporation stock logo
VCEL
Vericel
0.00%-4.58%-16.86%-28.95%-30.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$15.31
-0.2%
$13.90
$6.38
$16.66
$1.49B1.571.44 million shs1.46 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.68
-2.1%
$14.68
$12.79
$55.70
$1.59B1.022.50 million shs1.83 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$32.31
-1.1%
$25.63
$10.81
$33.63
$473.38M0.31121,077 shs70,513 shs
Vericel Corporation stock logo
VCEL
Vericel
$31.79
+5.2%
$35.10
$29.24
$63.00
$1.53B1.33926,935 shs1.21 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
0.00%-5.31%+3.93%+73.33%+20.31%
Biohaven Ltd. stock logo
BHVN
Biohaven
0.00%+4.53%-2.37%+6.24%-70.61%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%+18.41%+15.89%+129.01%+110.57%
Vericel Corporation stock logo
VCEL
Vericel
0.00%-4.58%-16.86%-28.95%-30.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.11
Buy$20.8636.23% Upside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.13
Buy$48.85232.74% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
2.80
Moderate Buy$60.4090.00% Upside

Current Analyst Ratings Breakdown

Latest INBX, VCEL, AVDL, and BHVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
9/17/2025
Vericel Corporation stock logo
VCEL
Vericel
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
9/16/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$27.00 ➝ $26.00
9/5/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$24.00 ➝ $36.00
9/3/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/3/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate BuyStrong-Buy
9/2/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageEqual Weight$16.00
9/2/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageStrong-Buy$75.00
8/22/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
8/21/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $20.00
(Data available from 9/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M8.79N/AN/A$0.77 per share19.88
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K2,339.24$115.39 per share0.28$9.23 per share3.50
Vericel Corporation stock logo
VCEL
Vericel
$237.22M6.76$0.33 per share96.74$5.92 per share5.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.03N/A255.17N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.12264.9472.25N/A2.85%2.47%1.69%11/6/2025 (Estimated)

Latest INBX, VCEL, AVDL, and BHVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92-$1.85+$1.07-$1.85N/A$1.30 million
8/11/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.94-$1.94N/A-$1.94$0.41 millionN/A
8/7/2025Q2 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$0.02$0.10+$0.08$0.10$60.28 million$68.13 million
7/31/2025Q2 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.79
2.38
Biohaven Ltd. stock logo
BHVN
Biohaven
1.91
3.82
3.82
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.45
4.98
4.98
Vericel Corporation stock logo
VCEL
Vericel
N/A
4.97
4.56

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
Biohaven Ltd. stock logo
BHVN
Biohaven
14.60%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
Vericel Corporation stock logo
VCEL
Vericel
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7097.10 million92.05 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239105.79 million90.35 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 millionN/AOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.46 million46.83 millionOptionable

Recent News About These Companies

Canaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)
Vericel (NASDAQ:VCEL) Hits New 52-Week Low Following Analyst Downgrade
Vericel (NASDAQ:VCEL) Shares Gap Down Following Analyst Downgrade
Vericel (NASDAQ:VCEL) Lowered to Neutral Rating by BTIG Research
Brokerages Set Vericel Corporation (NASDAQ:VCEL) Price Target at $60.40
Vericel downgraded to Neutral from Buy at BTIG
BTIG Downgrades Vericel (VCEL)
Vericel (NASDAQ:VCEL) Shares Down 5.8% - Here's Why

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$15.31 -0.03 (-0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$15.82 +0.51 (+3.33%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Biohaven stock logo

Biohaven NYSE:BHVN

$14.68 -0.32 (-2.13%)
Closing price 03:59 PM Eastern
Extended Trading
$14.88 +0.20 (+1.36%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$32.31 -0.37 (-1.13%)
Closing price 04:00 PM Eastern
Extended Trading
$32.30 -0.01 (-0.02%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$31.79 +1.56 (+5.16%)
Closing price 04:00 PM Eastern
Extended Trading
$31.82 +0.03 (+0.09%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.